{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T11:25:10Z","timestamp":1779103510788,"version":"3.51.4"},"reference-count":28,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Background: Physicians often use caution when prescribing statins to patients with chronic liver disease (CLD) due to potential hepatotoxicity. However, recent evidence indicates that hepatotoxicity is uncommon, and the risks of not using statins may often outweigh those associated with their use. Additionally, recent findings suggest that statins may have clinically beneficial effects on cirrhosis due to their pleiotropic properties.  Objective: To evaluate the impact of statin use on the number of patients with chronic liver disease alive at the end of the trials and to assess its effects on portal hypertension, ascites, hepatic encephalopathy, variceal hemorrhage, and hepatocellular carcinoma.  Methods: This meta-analysis analyzed 9 randomized clinical trials published in the MEDLINE, EMBASE, and SCOPUS databases that evaluated the use of statins in patients with cirrhosis. These studies included a total of 811 subjects with portal hypertension, of which 401 patients were in the intervention group. We assessed risk of bias using the Risk of Bias 2 (RoB 2) tool for randomized clinical trials, and we analyzed the quality of evidence using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) scale. We extracted data on the number of events and the total number of patients to perform a meta-analysis of proportions using the R software with the \u201cmeta\u201d package (version 4.9-6).  Results: Our meta-analysis on patients alive at the end of the trials included 5 studies, involving a total of 718 patients (352 in the statin group and 366 in the control group). From these, 618 patients were alive at the end of the studies, with 301 from the intervention group and 287 from the control group. The overall odds ratio (OR) between the groups was 1.79 (95%CI -1.04 to 3.06; I\u00b2: 20.3%), favoring the use of statins. The results for variceal gastrointestinal bleeding showed an OR of 0.67 (95%CI, 0.41 to 1.09; I\u00b2: 0%); for hemodynamic response, the OR was 2.41 (95%CI, 0.65 to 8.92; I\u00b2: 66%); for hepatic encephalopathy, the OR was 0.41 (95%CI, 0.06 to 2.77; I\u00b2: 61%); for myalgia, an OR of 0.74 (95%CI, 0.22 to 2.46; I\u00b2: 1%); and for ascites, the OR was 0.84 (95%CI, 0.48 to 1.48; I\u00b2: 0%).  Conclusion: The use of statins is associated with a greater number of patients with hepatic cirrhosis alive at the end of the trials. However, we were unable to determine the reason for this potential beneficial effect.<\/jats:p>","DOI":"10.1590\/s0004-2803.24612025-036","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:51:22Z","timestamp":1779101482000},"source":"Crossref","is-referenced-by-count":0,"title":["ROLE OF STATINS IN CIRRHOTIC PORTAL HYPERTENSION: META-ANALYSIS OF RANDOMIZED STUDIES"],"prefix":"10.1590","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7291-773X","authenticated-orcid":false,"given":"Mariana Oliveira Amarante","family":"MORENO","sequence":"first","affiliation":[{"name":"Escola Bahiana de Medicina e Sa\u00fade P\u00fablica,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9766-7324","authenticated-orcid":false,"given":"Cl\u00e1udio Luiz da Silva Lima","family":"PAZ","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9569-441X","authenticated-orcid":false,"given":"Mariana Alves Nascimento","family":"RODRIGUES","sequence":"additional","affiliation":[{"name":"Universidade Federal do Vale do S\u00e3o Francisco,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3005-8598","authenticated-orcid":false,"given":"Antonio Carlos Dias","family":"ANDRADE","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-220X","authenticated-orcid":false,"given":"Maria Gabriela Fernandes","family":"DEZAN","sequence":"additional","affiliation":[{"name":"Escola Bahiana de Medicina e Sa\u00fade P\u00fablica,  Brasil; Universidade Federal da Bahia,  Brasil; Universidade Federal da Bahia,  Brasil; Instituto Do\u2019r de Ensino e Pesquisa,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-0931","authenticated-orcid":false,"given":"Lourianne Nascimento","family":"CAVALCANTE","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia,  Brasil; Universidade Federal da Bahia,  Brasil; Instituto Do\u2019r de Ensino e Pesquisa,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9010-8645","authenticated-orcid":false,"given":"Andr\u00e9 Castro","family":"LYRA","sequence":"additional","affiliation":[{"name":"Universidade Federal da Bahia,  Brasil; Universidade Federal da Bahia,  Brasil; Instituto Do\u2019r de Ensino e Pesquisa,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref1","first-page":"759","article-title":"Cirrhosis: Diagnosis and management","volume":"100","author":"Smith A","year":"2019","journal-title":"Am Fam Physician"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"22232","DOI":"10.1038\/s41598-024-72795-0","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021","volume":"14","author":"Yang Z","year":"2024","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu YC","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis EA","year":"2014","journal-title":"Lancet"},{"key":"ref5","first-page":"957","article-title":"Portal hypertension in cirrhosis: A position statement by the Baveno VII Faculty","volume":"77","author":"Garcia-Tsao G","year":"2022","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3748\/wjg.v25.i8.888","article-title":"Current and future pharmacological therapies for managing cirrhosis and its complications","volume":"25","author":"Kockerling D","year":"2019","journal-title":"World J Gastroenterol"},{"key":"ref7","first-page":"S47","article-title":"An assessment by the Statin Liver Safety Task Force: 2014 update","volume":"8","author":"Bays H","year":"2014","journal-title":"J Clin Lipidol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1055\/s-0035-1564093","article-title":"The safety and benefit of statins in liver cirrhosis: a review","volume":"123","author":"Souk K","year":"2015","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11894-017-0584-7","article-title":"Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects","volume":"19","author":"Vargas JI","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2013.01.005","article-title":"Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies","volume":"11","author":"Rockey DC","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: old drugs as new therapy for liver diseases?","volume":"70","author":"Pose E","year":"2019","journal-title":"J Hepatol"},{"issue":"n71","key":"ref12","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","article-title":"Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial","volume":"136","author":"Abraldes JG","year":"2009","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.01.004","article-title":"Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis","volume":"150","author":"Abraldes JG","year":"2016","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/MEG.0000000000001006","article-title":"Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study","volume":"30","author":"Bishnu S","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s43066-021-00143-2","article-title":"Survival benefits of adding simvastatin to standard therapy for secondary prevention of bleeding esophageal varices in patients with hepatitis C-related liver cirrhosis","volume":"11","author":"Elshazly H","year":"2021","journal-title":"Egypt Liver J"},{"key":"ref17","first-page":"1229","article-title":"Evaluation of portal pressure by Doppler ultrasound in patients with cirrhosis before and after simvastatin administration: a randomized controlled trial","volume":"7","author":"Abd-Elsalam S","year":"2018","journal-title":"F1000Research"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"020","DOI":"10.29328\/journal.acgh.1001010","article-title":"Addition of simvastatin to carvedilol and endoscopic variceal ligation improves rebleeding and survival in patients with Child-Pugh A and B class but not in Child-Pugh C class","volume":"3","author":"Jha SK","year":"2019","journal-title":"Ann Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000332","article-title":"Atorvastatin for patients with cirrhosis: a randomized, placebo-controlled trial","volume":"7","author":"Kronborg TM","year":"2023","journal-title":"Hepatol Commun"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","article-title":"Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial","volume":"47","author":"Pollo-Flores P","year":"2015","journal-title":"Dig Liver Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.14309\/ajg.0000000000000551","article-title":"Hemodynamic effects of adding simvastatin to carvedilol for primary prophylaxis of variceal bleeding: a randomized controlled trial","volume":"115","author":"Vijayaraghavan R","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.3748\/wjg.v27.i28.4639","article-title":"Addition of statins to the standard treatment in patients with cirrhosis: safety and efficacy","volume":"27","author":"Mu\u00f1oz AE","year":"2021","journal-title":"World J Gastroenterol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1097\/HEP.0000000000000278","article-title":"Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC","volume":"78","author":"Sharpton SR","year":"2023","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s12876-019-1147-1","article-title":"Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis","volume":"19","author":"Gu Y","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"ref25","article-title":"Systematic review with a meta-analysis: clinical effects of statins on the reduction of portal hypertension and variceal haemorrhage in cirrhotic patients","volume":"9","author":"Wan S","year":"2019","journal-title":"BMJ Open"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3390\/molecules29081859","article-title":"A systematic review of statins for the treatment of nonalcoholic steatohepatitis: safety, efficacy, and mechanism of action","volume":"29","author":"Zhang S","year":"2024","journal-title":"Molecules"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"C522","DOI":"10.1152\/ajpcell.00406.2014","article-title":"The impact of statins on biological characteristics of stem cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects","volume":"309","author":"Izadpanah R","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/gutjnl-2024-333074","article-title":"Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease: results from the VCTE-Prognosis Study","volume":"73","author":"Zhou XD","year":"2024","journal-title":"Gut"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["Papel das estatinas na hipertens\u00e3o portal cirr\u00f3tica: metan\u00e1lise de estudos randomizados"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032026000101402&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:51:28Z","timestamp":1779101488000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032026000101402&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"alternative-id":["S0004-28032026000101402"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.24612025-036","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e25036"}}